These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 35132063)

  • 41. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bispecific Antibodies for Triple Negative Breast Cancer.
    Dees S; Ganesan R; Singh S; Grewal IS
    Trends Cancer; 2021 Feb; 7(2):162-173. PubMed ID: 33041246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Considerations for the Design of Antibody-Based Therapeutics.
    Goulet DR; Atkins WM
    J Pharm Sci; 2020 Jan; 109(1):74-103. PubMed ID: 31173761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody-drug conjugates in solid tumors: a look into novel targets.
    Criscitiello C; Morganti S; Curigliano G
    J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer therapy with bispecific antibodies: Clinical experience.
    Thakur A; Lum LG
    Curr Opin Mol Ther; 2010 Jun; 12(3):340-9. PubMed ID: 20521223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.
    Yoon A; Lee S; Lee S; Lim S; Park YY; Song E; Kim DS; Kim K; Lim Y
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32143496
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Not Available].
    Mallet A; Ombline C; Robert M; Campone M; Frenel JS
    Bull Cancer; 2021 Dec; 108(11S):11S19-11S25. PubMed ID: 34969512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bispecific antibodies: what future?].
    Pèlegrin A; Robert B
    Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties.
    Rossi EA; Chang CH; Cardillo TM; Goldenberg DM
    Bioconjug Chem; 2013 Jan; 24(1):63-71. PubMed ID: 23116517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
    Venugopal S; Daver N; Ravandi F
    Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bispecific and multispecific antibodies in oncology: opportunities and challenges.
    Goebeler ME; Stuhler G; Bargou R
    Nat Rev Clin Oncol; 2024 Jul; 21(7):539-560. PubMed ID: 38822215
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Danish bispecifics meet ADCs.
    Nat Biotechnol; 2020 Jul; 38(7):774. PubMed ID: 32641846
    [No Abstract]   [Full Text] [Related]  

  • 53. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
    Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
    J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
    Golay J; Introna M
    Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
    He Y; Helfrich W; Bremer E
    Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Current Progress and Future Developments of Antibody Drug Conjugates 
in Lung Cancer].
    Zhu Y; Wang Z
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):468-476. PubMed ID: 35899443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy in aggressive B-cell lymphomas.
    Jacobson CA; Armand P
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):299-305. PubMed ID: 30213400
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.
    Hendriks D; Choi G; de Bruyn M; Wiersma VR; Bremer E
    Int Rev Cell Mol Biol; 2017; 331():289-383. PubMed ID: 28325214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.